TY - JOUR
T1 - CD4+ CD56+ hematodermic/plasmacytoid dendritic cell tumor with response to pralatrexate
AU - Leitenberger, Justin J.
AU - Berthelot, Cindy N.
AU - Polder, Kristel D.
AU - Pro, Barbara
AU - McLaughlin, Peter
AU - Jones, Dan
AU - Duvic, Madeleine
N1 - Funding Information:
Supported in part by Sherry L. Anderson Cutaneous T-cell Lymphoma Research Fund, National Institutes of Health Grant K24-CA86815, and MD Anderson Core Grant CA16672.
PY - 2008/3
Y1 - 2008/3
N2 - The CD4+ CD56+ hematodermic/plasmacytoid dendritic cell tumor is a rare, highly aggressive, systemic neoplasm for which effective therapies have not yet been established. These tumors express CD4, CD56, CD123, and T-cell leukemia/lymphoma (TCL)-1 and are clinically characterized by cutaneous involvement with spread to bone marrow and blood, and poor prognosis with current chemotherapy regimens. We describe a Caucasian woman who presented with plasmacytoid dendritic cell tumor, but an absence of systemic symptoms. Clinically, multiple cutaneous lesions were brown to violaceous firm nodules on the face, arms, and trunk. The patient underwent two courses of cyclophosphamide, Adriamycin, vincristine, and prednisone chemotherapy but relapsed quickly. The investigational agent, pralatrexate (30 mg/m2) was given weekly with vitamin B12 and folic acid and resulted in remarkable clinical response with regression of skin tumors. Our observation highlights pralatrexate as a promising therapeutic option for hematodermic/plasmacytoid dendritic cell lymphoma/leukemias.
AB - The CD4+ CD56+ hematodermic/plasmacytoid dendritic cell tumor is a rare, highly aggressive, systemic neoplasm for which effective therapies have not yet been established. These tumors express CD4, CD56, CD123, and T-cell leukemia/lymphoma (TCL)-1 and are clinically characterized by cutaneous involvement with spread to bone marrow and blood, and poor prognosis with current chemotherapy regimens. We describe a Caucasian woman who presented with plasmacytoid dendritic cell tumor, but an absence of systemic symptoms. Clinically, multiple cutaneous lesions were brown to violaceous firm nodules on the face, arms, and trunk. The patient underwent two courses of cyclophosphamide, Adriamycin, vincristine, and prednisone chemotherapy but relapsed quickly. The investigational agent, pralatrexate (30 mg/m2) was given weekly with vitamin B12 and folic acid and resulted in remarkable clinical response with regression of skin tumors. Our observation highlights pralatrexate as a promising therapeutic option for hematodermic/plasmacytoid dendritic cell lymphoma/leukemias.
UR - http://www.scopus.com/inward/record.url?scp=38949153794&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=38949153794&partnerID=8YFLogxK
U2 - 10.1016/j.jaad.2007.12.012
DO - 10.1016/j.jaad.2007.12.012
M3 - Article
C2 - 18280345
AN - SCOPUS:38949153794
SN - 0190-9622
VL - 58
SP - 480
EP - 484
JO - Journal of the American Academy of Dermatology
JF - Journal of the American Academy of Dermatology
IS - 3
ER -